NO762660L - - Google Patents
Info
- Publication number
- NO762660L NO762660L NO762660A NO762660A NO762660L NO 762660 L NO762660 L NO 762660L NO 762660 A NO762660 A NO 762660A NO 762660 A NO762660 A NO 762660A NO 762660 L NO762660 L NO 762660L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- het
- compound
- compounds
- histamine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 31
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical group [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 239000007800 oxidant agent Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 239000005864 Sulphur Substances 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 3
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical group OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- JVYMKTAPCLSXLC-UHFFFAOYSA-N COClO Chemical group COClO JVYMKTAPCLSXLC-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 2
- -1 sulfoxide compounds Chemical class 0.000 description 19
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 6
- 150000003462 sulfoxides Chemical class 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 3
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEFSTZFKZGBJHW-UHFFFAOYSA-N 2-nitro-1-n,1-n'-bis[2-(1,3-thiazol-2-ylmethylsulfanyl)ethyl]ethene-1,1-diamine Chemical group N=1C=CSC=1CSCCNC(=C[N+](=O)[O-])NCCSCC1=NC=CS1 HEFSTZFKZGBJHW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- GJEAMHAFPYZYDE-UHFFFAOYSA-N [C].[S] Chemical compound [C].[S] GJEAMHAFPYZYDE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002541 isothioureas Chemical class 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB31969/75A GB1565205A (en) | 1975-07-31 | 1975-07-31 | Heterocyclic sulphoxides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO762660L true NO762660L (un) | 1977-02-01 |
Family
ID=10331088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO762660A NO762660L (un) | 1975-07-31 | 1976-07-30 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US4038408A (un) |
| JP (1) | JPS5219662A (un) |
| AR (1) | AR216056A1 (un) |
| AU (1) | AU1645476A (un) |
| BE (1) | BE844503R (un) |
| BG (1) | BG27361A3 (un) |
| CA (1) | CA1069904A (un) |
| CH (1) | CH609683A5 (un) |
| CS (1) | CS203102B2 (un) |
| DD (1) | DD126081A5 (un) |
| DE (1) | DE2634432A1 (un) |
| DK (1) | DK316076A (un) |
| ES (1) | ES450318A2 (un) |
| FI (1) | FI762192A (un) |
| FR (1) | FR2361881A2 (un) |
| GB (1) | GB1565205A (un) |
| HU (1) | HU173928B (un) |
| IN (1) | IN146152B (un) |
| LU (1) | LU75493A1 (un) |
| NL (1) | NL7608491A (un) |
| NO (1) | NO762660L (un) |
| OA (1) | OA05404A (un) |
| PL (1) | PL191535A1 (un) |
| RO (1) | RO70855B (un) |
| SE (1) | SE7608476L (un) |
| SU (1) | SU618044A3 (un) |
| ZA (1) | ZA763837B (un) |
| ZM (1) | ZM9776A1 (un) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151289A (en) * | 1975-01-22 | 1979-04-24 | Smith Kline & French Laboratories Limited | Nitromethylene amidino derivatives containing imidazole groups |
| NZ186965A (en) * | 1977-04-20 | 1980-02-21 | Ici Ltd | Guanidino derivatives and pharmaceutical compositions |
| DE2817078C2 (de) * | 1977-04-20 | 1995-06-14 | Zeneca Ltd | Guanidinderivate |
| US4165378A (en) * | 1977-04-20 | 1979-08-21 | Ici Americas Inc. | Guanidine derivatives of imidazoles and thiazoles |
| US4233302A (en) * | 1977-12-23 | 1980-11-11 | Glaxo Group Limited | Amine derivatives and pharmaceutical compositions containing them |
| EP0014057B1 (en) * | 1979-01-18 | 1985-01-02 | Imperial Chemical Industries Plc | Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them |
| US4220654A (en) * | 1979-06-04 | 1980-09-02 | Merck & Co., Inc. | Cyclic imidazole cyanoguanidines |
| EP4196793A1 (en) | 2020-08-11 | 2023-06-21 | Université de Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1421999A (en) * | 1973-02-08 | 1976-01-21 | Smith Kline French Lab | Heterocyclic containing sulphoxides |
-
1975
- 1975-07-31 GB GB31969/75A patent/GB1565205A/en not_active Expired
-
1976
- 1976-06-28 ZA ZA763837A patent/ZA763837B/xx unknown
- 1976-07-05 IN IN1187/CAL/76A patent/IN146152B/en unknown
- 1976-07-13 US US05/704,871 patent/US4038408A/en not_active Expired - Lifetime
- 1976-07-13 DK DK316076A patent/DK316076A/da unknown
- 1976-07-21 CS CS764840A patent/CS203102B2/cs unknown
- 1976-07-22 CA CA257,550A patent/CA1069904A/en not_active Expired
- 1976-07-23 BE BE169227A patent/BE844503R/xx active
- 1976-07-23 ZM ZM97/76A patent/ZM9776A1/xx unknown
- 1976-07-27 FR FR7622849A patent/FR2361881A2/fr active Granted
- 1976-07-27 SE SE7608476A patent/SE7608476L/xx unknown
- 1976-07-29 DD DD194123A patent/DD126081A5/xx unknown
- 1976-07-29 LU LU75493A patent/LU75493A1/xx unknown
- 1976-07-30 BG BG7633886A patent/BG27361A3/xx unknown
- 1976-07-30 SU SU762386216A patent/SU618044A3/ru active
- 1976-07-30 JP JP51092244A patent/JPS5219662A/ja active Pending
- 1976-07-30 ES ES450318A patent/ES450318A2/es not_active Expired
- 1976-07-30 FI FI762192A patent/FI762192A/fi not_active Application Discontinuation
- 1976-07-30 HU HU76SI1530A patent/HU173928B/hu unknown
- 1976-07-30 PL PL19153576A patent/PL191535A1/xx unknown
- 1976-07-30 AU AU16454/76A patent/AU1645476A/en not_active Expired
- 1976-07-30 DE DE19762634432 patent/DE2634432A1/de not_active Withdrawn
- 1976-07-30 NL NL7608491A patent/NL7608491A/xx not_active Application Discontinuation
- 1976-07-30 CH CH978476A patent/CH609683A5/xx not_active IP Right Cessation
- 1976-07-30 AR AR264158A patent/AR216056A1/es active
- 1976-07-30 NO NO762660A patent/NO762660L/no unknown
- 1976-07-31 OA OA55902A patent/OA05404A/xx unknown
- 1976-07-31 RO RO87166A patent/RO70855B/ro unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE844503R (fr) | 1977-01-24 |
| DK316076A (da) | 1977-02-01 |
| CA1069904A (en) | 1980-01-15 |
| SU618044A3 (ru) | 1978-07-30 |
| LU75493A1 (un) | 1977-03-03 |
| CS203102B2 (en) | 1981-02-27 |
| OA05404A (fr) | 1981-02-28 |
| CH609683A5 (un) | 1979-03-15 |
| BG27361A3 (en) | 1979-10-12 |
| RO70855B (ro) | 1984-03-31 |
| SE7608476L (sv) | 1977-02-01 |
| FR2361881B2 (un) | 1979-04-13 |
| DE2634432A1 (de) | 1977-02-10 |
| AR216056A1 (es) | 1979-11-30 |
| NL7608491A (nl) | 1977-02-02 |
| DD126081A5 (un) | 1977-06-15 |
| GB1565205A (en) | 1980-04-16 |
| IN146152B (un) | 1979-03-10 |
| ZM9776A1 (en) | 1977-09-21 |
| RO70855A (ro) | 1984-03-15 |
| JPS5219662A (en) | 1977-02-15 |
| PL191535A1 (pl) | 1978-04-10 |
| FI762192A (un) | 1977-02-01 |
| FR2361881A2 (fr) | 1978-03-17 |
| ZA763837B (en) | 1977-05-25 |
| ES450318A2 (es) | 1977-10-01 |
| AU1645476A (en) | 1978-02-02 |
| US4038408A (en) | 1977-07-26 |
| HU173928B (hu) | 1979-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3953460A (en) | Ethylene derivatives | |
| US4013678A (en) | Process for preparing heterocyclicalkylthioalkyl-n-cyanoguanidines | |
| IE47363B1 (en) | Imidazole derivatives | |
| EP0040696A2 (en) | Aminothiadiazoles as gastric secretion inhibitors | |
| CA1125778A (en) | Pleuromutilin derivatives, their production and use | |
| NO143942B (no) | Analogifremgangsmaate for fremstilling av farmakologisk aktive heterocyklisk substituerte guanidiner | |
| CA1068711A (en) | Preparation of alkoxypyridyl derivatives which are histamine h2-antangonists | |
| US4049671A (en) | Process for preparing N-cyanoguanidines | |
| NO762660L (un) | ||
| US4265896A (en) | Amidinosulphonic acid derivatives | |
| US4308275A (en) | Thiazole and isothiazole compounds, pharmaceutical compositions and their method of use | |
| NO762659L (un) | ||
| US4156727A (en) | Alkoxy pyridine compounds | |
| US4228291A (en) | Pharmacologically active thiadiazole guanidine compounds | |
| NO781572L (no) | Fremgangsmaate for fremstilling av bisamidiner | |
| US4046907A (en) | Imidazole alkylaminoethylene compounds | |
| NO784350L (no) | Fremgangsmaate til alkylering av 4(5)-merkaptometyl-imidazoler med aziridinderivater | |
| US4166856A (en) | Thiazole and isothiazole derivative as blockers of histamine H2 -receptors | |
| US4277485A (en) | Oxazole or isoxazole alkylamino ethylene compounds as inhibitors of H-2 histamine receptors | |
| US4105770A (en) | Heterocyclomethylsulphinylethyl derivatives of N-cyanoguanidines, thioureas and 2-amino-1-nitroethylene | |
| US4024260A (en) | Ethylene derivatives | |
| US4083988A (en) | Pharmacologically active compounds | |
| US4093729A (en) | N-Oxy and N-amino guanidines | |
| US4090026A (en) | Certain nitrogen heterocyclic isothiocyanate esters | |
| US4200761A (en) | Process for preparing N-cyano-N'methyl-N"-{2-[(4-methyl-5-imidazolyl)-methylthio]-ethyl} guanidine |